i-SENS, Inc. (099190.KQ)
KRW 15190.0
(-0.72%)
KRW 15190.0
(-0.72%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 265.12 Billion KRW | 0.11% |
| 2022 | 264.83 Billion KRW | 13.7% |
| 2021 | 232.93 Billion KRW | 14.35% |
| 2020 | 203.7 Billion KRW | 7.3% |
| 2019 | 189.84 Billion KRW | 9.74% |
| 2018 | 172.99 Billion KRW | 10.21% |
| 2017 | 156.96 Billion KRW | 18.49% |
| 2016 | 132.46 Billion KRW | 29.97% |
| 2015 | 101.92 Billion KRW | 6.6% |
| 2014 | 95.6 Billion KRW | 15.38% |
| 2013 | 82.86 Billion KRW | 24.51% |
| 2012 | 66.54 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 70.34 Billion KRW | 0.63% |
| 2024 Q1 | 68.7 Billion KRW | -8.33% |
| 2024 Q2 | 69.9 Billion KRW | 1.75% |
| 2023 Q2 | 62.48 Billion KRW | 3.04% |
| 2023 FY | 265.12 Billion KRW | 0.11% |
| 2023 Q1 | 60.64 Billion KRW | -7.74% |
| 2023 Q3 | 67.03 Billion KRW | 7.28% |
| 2023 Q4 | 74.94 Billion KRW | 11.79% |
| 2022 Q2 | 61.76 Billion KRW | -10.26% |
| 2022 Q1 | 68.82 Billion KRW | 9.3% |
| 2022 FY | 264.83 Billion KRW | 13.7% |
| 2022 Q4 | 65.73 Billion KRW | -4.05% |
| 2022 Q3 | 68.51 Billion KRW | 10.93% |
| 2021 FY | 232.93 Billion KRW | 14.35% |
| 2021 Q2 | 58.37 Billion KRW | 11.03% |
| 2021 Q3 | 59 Billion KRW | 1.08% |
| 2021 Q1 | 52.58 Billion KRW | -5.75% |
| 2021 Q4 | 62.96 Billion KRW | 6.7% |
| 2020 Q3 | 50.54 Billion KRW | -4.19% |
| 2020 FY | 203.7 Billion KRW | 7.3% |
| 2020 Q4 | 55.78 Billion KRW | 10.38% |
| 2020 Q2 | 52.75 Billion KRW | 18.23% |
| 2020 Q1 | 44.62 Billion KRW | -17.21% |
| 2019 FY | 189.84 Billion KRW | 9.74% |
| 2019 Q4 | 53.89 Billion KRW | 10.66% |
| 2019 Q3 | 48.7 Billion KRW | 5.2% |
| 2019 Q2 | 46.3 Billion KRW | 13.1% |
| 2019 Q1 | 40.93 Billion KRW | -15.06% |
| 2018 Q3 | 45.67 Billion KRW | 11.9% |
| 2018 FY | 172.99 Billion KRW | 10.21% |
| 2018 Q2 | 40.81 Billion KRW | 6.56% |
| 2018 Q1 | 38.3 Billion KRW | -12.0% |
| 2018 Q4 | 48.19 Billion KRW | 5.51% |
| 2017 Q2 | 37.34 Billion KRW | 3.88% |
| 2017 FY | 156.96 Billion KRW | 18.49% |
| 2017 Q1 | 35.95 Billion KRW | -3.59% |
| 2017 Q3 | 40.13 Billion KRW | 7.49% |
| 2017 Q4 | 43.52 Billion KRW | 8.44% |
| 2016 FY | 132.46 Billion KRW | 29.97% |
| 2016 Q2 | 32.94 Billion KRW | 14.76% |
| 2016 Q1 | 28.7 Billion KRW | 8.49% |
| 2016 Q3 | 33.52 Billion KRW | 1.75% |
| 2016 Q4 | 37.29 Billion KRW | 11.24% |
| 2015 Q1 | 22.82 Billion KRW | -7.27% |
| 2015 Q4 | 26.46 Billion KRW | 3.91% |
| 2015 Q2 | 27.16 Billion KRW | 19.01% |
| 2015 Q3 | 25.46 Billion KRW | -6.26% |
| 2015 FY | 101.92 Billion KRW | 6.6% |
| 2014 Q3 | 22.7 Billion KRW | -10.6% |
| 2014 FY | 95.6 Billion KRW | 15.38% |
| 2014 Q1 | 22.88 Billion KRW | 1.6% |
| 2014 Q4 | 24.61 Billion KRW | 8.39% |
| 2014 Q2 | 25.4 Billion KRW | 11.02% |
| 2013 Q1 | 19.02 Billion KRW | -12.05% |
| 2013 Q2 | 21.06 Billion KRW | 10.72% |
| 2013 FY | 82.86 Billion KRW | 24.51% |
| 2013 Q3 | 20.25 Billion KRW | -3.85% |
| 2013 Q4 | 22.52 Billion KRW | 11.2% |
| 2012 Q3 | 15.99 Billion KRW | 0.0% |
| 2012 Q4 | 21.62 Billion KRW | 35.24% |
| 2012 FY | 66.54 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 355.84 Billion KRW | 25.496% |
| InBody Co.,Ltd | 170.35 Billion KRW | -55.632% |
| Curexo Inc. | 72.88 Billion KRW | -263.765% |
| Seegene, Inc. | 367.37 Billion KRW | 27.834% |
| Ray Co., Ltd. | 145.88 Billion KRW | -81.736% |
| Gencurix Inc. | 2.6 Billion KRW | -10095.687% |
| Sugentech Inc. | 7.13 Billion KRW | -3617.175% |
| L&C Bio Co., Ltd | 68.86 Billion KRW | -284.96% |